Cargando…
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Clear cell renal cell carcinoma (ccRCC) is the seventh most frequently diagnosed tumor in adults in Europe and represents approximately 2.5% of cancer deaths. The molecular biology underlying renal cell carcinoma (RCC) development and progression has been a key milestone in the management of this ty...
Autores principales: | Alonso-Gordoa, Teresa, García-Bermejo, María Laura, Grande, Enrique, Garrido, Pilar, Carrato, Alfredo, Molina-Cerrillo, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515337/ https://www.ncbi.nlm.nih.gov/pubmed/30999623 http://dx.doi.org/10.3390/ijms20081901 |
Ejemplares similares
-
Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020) -
Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2022) -
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
por: San Román Gil, María, et al.
Publicado: (2020) -
Novel Tyrosine Kinase Targets in Urothelial Carcinoma
por: Torres-Jiménez, Javier, et al.
Publicado: (2021) -
Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)